This page is updated frequently with new Clinical Trial-related patent applications.
| Ancestral-specific reference genomes and uses in identifying a candidate for a clinical trial|
Ancestry has a significant impact on the major and minor alleles found in each nucleotide position within the genome. Due to mechanisms of inheritance, ancestral-specific information contained within the genome is conserved within members of an ancestry.
Inova Health System
|Event based managing clinical trial data|
A system and method for integrating clinical trial data housed in disparate systems. The integration system listens for a clinical trial event broadcasted by any one of the disparate systems.
Inc Research, Llc
|System and verifying viewing of multimedia rendering of investigator meeting prefatory to clinical trial participation|
A system and method providing passive verification of participant—typically a physician—exposure to material equivalent to attendance at an investigator meeting prefatory to clinical trial is taught. The invention provides for rendering media capture of investigator meeting education into computer deliverable sessions, and further into segments, where segments are the product of randomly generated visual requests to which participant need provide response in some prescribed time interval to confirm visual attention to material.
|Method and virtual clinical trial self-recruitment marketplace for patients based on behavioral stratification, patient engagement and patient management during clinical trials using behavioral analytics, gamification and cognitive techniques|
Method, apparatus and non-transitory computer readable media that enhance patient-recruitment and participation in clinical trials preferably includes structure and/or steps whereby one or more apis are used to interface at least one cognitive analytics value inference and intelligence—healthcare (cavii-h) server with the patient(s), pharma participant(s), contract research organization(s), trial investigator(s), and healthcare providers (such as a physician). The at least one cavii-h server preferably use at least one of stored trial data, user medical data, user behavioral date, user application collected data user registration data, healthcare professional data to guide patient participation.
|Persevere-ii: redefining the pediatric sepsis biomarker risk model with septic shock phenotype|
The methods disclosed herein relate to an improved tool incorporating platelet count into a multi-biomarker based outcome risk stratification model for evaluating mortality risk in pediatric patients having sepsis. The methods described here are useful for treating sepsis, for point of care clinical decision support, for stratifying septic shock patients based on baseline mortality risk, and for clinical trial design, among other uses..
Children's Hospital Medical Center
|Device and clinical data sampling and specimen banking|
A system and method are described that allow the autonomous collection of relevant data and samples from a patient during a clinical trial or during routine care. Sampling is accomplished by drawing multiple samples into tubing, such as microfluidic tubing, and using a pump to move the samples through the tubing.
Carnegie Mellon University, A Pennsylvania Non-pro Fit Corporation
|Remote monitoring and dynamic document management systems and methods|
Systems, methods, and computer-readable media are disclosed for remote monitoring and dynamic document management. Example methods may include receiving a first document from a device driver associated with a hardware device, identifying a clinical trial identifier associated with the first document based at least in part on metadata associated with the first document, and determining a first document type of the first document by analyzing contents of the first document.
Florence Healthcare, Inc.
|Computer-assisted adaptive, risk-based monitoring of clinical studies|
A method and system are described for continuously assessing the quality of field data in a clinical study, identifying clinical sites with weaker performance than other sites, and flexibly allocating resources to address the problems, including the need to send field monitors to a site. The sites are compared with respect to the number of database entries requiring verification, and a higher priority (for allocation of management resources) is given to sites that have generated higher numbers of unverified database entries.
|Risk assessment for therapeutic drugs|
Methods to estimate safety and/or efficacy of therapeutic drugs, which include portable devices for anti-drug antibody (ada) testing and databases containing anonymized data from human and/or animal models and related analyses, are provided. These methods and compositions can be used in various applications, including but not restricted to the following: uniform testing of patients for ada; selection of therapeutic drug for patient treatment; evaluation of the need to change therapeutic drug or to apply tolerance regimens; selection of patients for clinical trials; comparison of therapeutic drugs marketed for a given disease and also gene therapy; scientific guidance for discovering and/or developing therapeutic drugs; postmarketing surveillance of therapeutic drugs..
|Apparatus, systems, and methods for measuring environmental exposure and physiological response thereto|
Systems and methods for monitoring various physiological and environmental factors, as well as systems and methods for using this information for a plurality of useful purposes, are provided. Real-time, noninvasive health and environmental monitors include a plurality of compact sensors integrated within small, low-profile devices.
Identification of candidates for clinical trials
A system, a method, and a computer program product for identifying candidates for a clinical study are disclosed. A subject matter query for a study is received.
Medical clinical trial site identification
A method and system for identifying clinical trial sites is provided. The method includes receiving clinical trial data associated with a plurality of planned clinical trials.
International Business Machines Corporation
Systems and methods of a mobile application and web-interface for tracking complete chain-of-custody of laboratory assets
A mobile application (mobile app) runs on a mobile device to virtually establish, coordinate, and maintain chain of custody of laboratory sample specimens so as to facilitate inventory management, custodianship, notifications, query, resulting, and other duties of sample management. This is also known as virtual accessioning.
Distributed randomization and supply management in clinical trials
A distributed clinical trial system that provides configurability, reusability and integration of randomization and inventory configurations for different clinical trials with various electronic data capture (edc) systems. The distributed clinical trial system includes a method of dispensing medication in a multi-arm clinical trial.
Medidata Solutions, Inc.
Distributed randomization and supply management in clinical trials
A distributed clinical trial system that provides configurability, reusability and integration of randomization for different clinical trials with various electronic data capture (edc) systems. The distributed clinical trial system includes a method of randomizing subjects in a multi-arm clinical trial.
Medidata Solutions, Inc.
Method for creating and using registry of clinical trial participants
A method of screening participants for a clinical trial by obtaining identifying information chosen from a biometric sample, personal information, physical attributes, and combinations thereof from a prospective participant, generating a unique identifier code, populating a database with the unique identifier code and participant information and storing the database on computer readable media, screening the participant for a clinical trial based on the unique identifier code and participant information and searching for a match with another participant, searching for protocol violations, and determining eligibility of the participant for the clinical trial and preventing the protocol violations. A system for screening participants for a clinical trial..
System and matching patients with clinical trials
The current invention discloses improved systems and processes for increasing clinical trial enrollment. Information for a clinical trial is received, such as the disease or condition under investigation and the pharmaceutical, device, or therapy under investigation and stored as a clinical trial record.
Bionews Services, Llc
Biomarkers of alzheimer's disease progression
Provided is a method for measuring the propensity of a patient to suffer progression of alzheimer's disease that comprises, in either order: a) conducting a first immunoassay of a patient sample to determine the content (tau-c′) of a c-terminal epitope present at the terminus of the amino acid sequence -sstgsidmvd (seq id no:1), and b) conducting a second immunoassay of the sample to determine the content (tau-a′) of an n-terminal epitope present at the terminus of the amino acid sequence tprgaappgq- (seq id no:2), and c) calculating an index as a ratio tau-a′/tau-c′ between the second level and the first level. The method may be used to select patients for a clinical trial of an intervention in alzheimer's disease or to evaluate a therapy..
Nordic Bioscience A/s
Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
One side-effect arising from the use of antibodies against tnf receptor family members as therapeutics can be liver damage which precludes the completion of clinical trial. A novel lt-dependent pathway is described that mediates liver cell injury in several disease models..
The University Of Chicago
System and preparation of clinical trial budgets
Medical and other research organizations, sites within those organizations, and physicians practicing at those sites register in an online database. The company providing the database posts a description of a clinical trial opportunity or other research opportunity.
Process for the preparation of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
The invention relates to an improved process for synthesizing n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (i) compound (i) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.. .
Bristol-myers Squibb Company
Method to decrease brain injury following cerebral ischemia
A method to immediately treat cerebral ischemia caused by hemorrhage, thrombosis or spasm is described. The method requires an apparatus comprising a tight fitting non-rebreathing mask with one way expiratory valves and a pressure regulated source of compressed oxygen.
Reverse vaccination therapy of multiple sclerosis
Disclosed are means of inducing antigen-specific tolerance through genetically modifying msc to express antigens of interest in an inducible manner or constitutive manner. Msc have been demonstrated to suppress pathological immunity in an antigen-nonspecific manner in vitro and in vivo, including clinical trials of gvhd, type 1 diabetes, and multiple sclerosis.
Creative Medical Health, Llc
Therapy for subarachnoid hemorrhage and ischemia
The application provides data from a clinical trial of a psd-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the cns. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery.
Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines
Disclosed herein are diagnostic assays for identifying individuals that are protected against plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects.
The United States Of America,as Represented By The Secretary, Department Of Health And Human Service
Dispenser for dispensing a unitary dose of an active substance in a solid dosage form
The invention concerns a secure device for dispensing unit doses (mi) of an active substance in a solid dosage form. Such a device comprises means to prevent refilling of the chamber containing the unit doses.
System and determining a clinical trial patient burden
An improved clinical trial patient burden calculating system includes a data analyzer to calculate scores and weights for patient burden components, a plurality of data calculators to calculate a respective plurality of sub patient burden indexes based on the patient burden component scores and weights, and an aggregator to calculate a procedure-level patient burden index based on aggregation of the sub patient burden indexes. An improved method for calculating clinical trial patient burden is also described and claimed..
Medidata Solutions, Inc.
Systems and methods for matching patients with clinical trials
Systems and methods for matching of patients with clinical trials are described herein. The matching can be performed in an automated fashion and integrated with an existing clinical workflow.
University Hospitals Cleveland Medical Center
Drug delivery device
Drug delivery devices are described that include sensors and processing circuitry that can detect operating events, such as flow rates and drug delivery, in various types of inhalers, such as dry powder inhalers, metered dose inhalers, nasal inhalers and nebulisers. The information determined by the processing circuitry can be used to provide feedback to the user or can be stored or transmitted for subsequent analysis.
Cloud based emr manager
Methods are directed at utilizing a patient's electronic medical record (emr) information accessed from a cloud, such as that used in blue button technology. Once the patient's emr information is downloaded from the cloud, it is used to automatically determine if the patient is eligible to participate in a clinical trial.
Clinical trial management
Methods are directed at utilizing a cloud-based application for notifying a healthcare provider, such as a hospital or urgent care facility, that one or more patients from the healthcare provider qualify for clinical trial participation. A cloud-based application is also utilized for notifying one or more clinical trial sponsors, such as a university or pharmaceutical company, that one or more patients from one or more healthcare providers fulfill clinical trial eligibility.
Method and producing regulatory-compliant software
A system for producing a clinical trial software application includes a processor, comprising a validation service and an audit service, and a platform, configured to prove-in an infrastructure on which the software application operates. The software application operating on the infrastructure is the same as the software application previously validated in a validation portal.
System and determining site performance
An improved system for determining clinical trial site performance includes a site data filter for separating data corresponding to a clinical trial site into at least one site performance factor category data stream, where each site performance factor category comprises at least one site performance factor and each factor comprises at least one factor choice, a data stream analyzer for analyzing the site performance factor category data stream to determine a factor choice met for each site performance factor and to output a value for the determined factor choice, where the determined factor choice is multiplied by a weighting value, and an aggregator for aggregating the weighted, determined factor choices into a site performance index, where the weighting value is adjusted based on a user's input. An improved method for determining clinical trial site performance is also described and claimed..
Method and system for determining a site performance index
A method for determining a site performance index includes receiving data from one or more clinical trial sites, associating the clinical trial site data with at least one site performance factor, calculating a weighting value for the site performance factor, and generating the site performance index based on the weighted site performance factor. An apparatus for determining a site performance index is also described and claimed and includes a site data filter, a data stream analyzer, and an aggregator..
System and conducting in silico clinical trials
Described herein are computer systems and methods for generating, in silico, one or more virtual patients. The one or more virtual patients can be used, for example, to conduct a virtual clinical trial, such as to determine an efficacy of a therapy or medical device.